AbbVie Partners With Boehringer To Take On Stelara In Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III anti-IL-23 candidate BI 655066 bested Stelara for several measures of efficacy in a Phase II head-to-head study. AbbVie is paying $595m up front for rights to the antibody.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.